Hybribio Biotech: Subsidiary's six respiratory pathogen nucleic acid detection kits have obtained medical device registration certificates

On the evening of September 29, Hybribio Biotech announced that its wholly-owned subsidiary, Guangzhou Hybribio Pharmaceutical Technology Co., Ltd., received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for six nucleic acid detection kits for respiratory pathogens. This kit is used for the in vitro qualitative detection of nucleic acids of respiratory syncytial virus, influenza A virus, influenza B virus, adenovirus, parainfluenza virus, and Mycoplasma pneumoniae in nasopharyngeal swab samples